The Dermatology Digest

DECEMBER 13, 2024

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) for the treatment of patients aged 12 and older with moderate to severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.

Dermatitis 69

Dermatitis Safety Eczema Dermatology 69

The Dermatology Digest

SEPTEMBER 23, 2024

has given its official nod to delgocitinib (Anzupgo, Leo Pharma) cream for adults with moderate to severe chronic hand eczema (CHE). These trials evaluated the safety and efficacy of delgocitinib compared to cream vehicle. the new drug application, if approved, would make delgocitinib cream the first treatment in the U.S.

Eczema 66

Eczema Safety Dermatology Clinic 66

The Dermatology Digest

FEBRUARY 8, 2024

Psoriasis is also undergoing a revolution with the development of new oral treatments that act like injectable biologics, and this is of interest to patients who do not want a shot,” he says. It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” What’s next? “We

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

JANUARY 24, 2024

Delgocitinib cream demonstrated a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules in people with severe chronic hand eczema, according to results from the DELTA FORCE Trial, which is the first head-to-head phase 3 trial comparing a systemic and topical treatment for CHE.

Eczema 36

Eczema Safety Office Treatments 36

The Dermatology Digest

JANUARY 13, 2025

Results from multiple clinical trials showed that rezpegaldesleukin safely and dose-dependently increased Tregs and rapidly improved measurable exploratory disease outcomes in patients with moderate-to-severe AD that were largely durable for at least 36 weeks after ceasing treatment, demonstrating proof-of-concept in this indication.

Dermatitis 36

Dermatitis Clinic Eczema Therapy 36

Aesthetics Advisor

MARCH 10, 2024

Infants of mothers randomized to cut out eggs, milk, and fish were significantly less likely to have eczema even years later. Eczema, also known as atopic dermatitis, is a chronic inflammatory skin disease. Previously, I talked about the safety and efficacy of other, more natural treatments. But what about diet?

Eczema 36

Eczema Diet Dermatitis Document 36

The Dermatology Digest

JANUARY 15, 2024

Delgocitinib cream continues to perform well in chronic hand eczema (CHE) with limited systemic exposure, according to two studies presented at the 2024 Winter Clinical Dermatology Conference in Honolulu, Hawaii. This trial included samples from 313 people on active treatment.

Safety 36

Safety Eczema Dermatology Treatments 36

The Dermatology Digest

FEBRUARY 9, 2024

Brian Hilberdink, Leo Pharma’s EVP of North America, chatted with TDD about the significance of this study and the deleterious effect that chronic hand eczema can have on a person’s quality of life. Patients living with chronic hand eczema are impacted in their everyday lives and experience social, psychological, and physical effects.

Eczema 36

Eczema Marketing Dermatitis Dermatology 36

The Dermatology Digest

JANUARY 21, 2024

Delgocitinib cream continues to perform well in chronic hand eczema (CHE), with limited systemic exposure, according to two studies presented at the 2024 Maui Dermatology conference. What’s more, delgocitinib cream 20 mg/g was well-tolerated over 16 weeks, and no safety concerns were identified.

Safety 36

Safety Eczema Social Media Dermatology 36

The Dermatology Digest

MAY 16, 2024

million, five-year National Institutes of Health (NIH) U01 grant to investigate dupilumab (Dupixent, Sanofi & Regeneron) as a treatment for children with alopecia areata. Current treatment options for alopecia areata harbor negative side effects for long-term use. Dr. Guttman. “If

Eczema 69

Eczema Dermatitis Clinic Innovations 69

Eminence Organics

JULY 3, 2024

Absolutely, if you visit a spa professional for your treatment. Also known as "microplaning" or "blading," dermablading is a professional skin care treatment that skims the face with an exfoliating blade, specifically created for use on the skin. Always go to a spa to do this treatment, don't try to do it at home.

Dermaplaning 98

Dermaplaning Hair Removal Facials Tools 98

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). The FDA has granted nemolizumab Priority Review for prurigo nodularis.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

First Derm

FEBRUARY 21, 2024

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. There’s a crucial difference between cosmetic retinol use and medical treatment with retinoids ; the latter is for specific skin conditions under professional supervision.

Retinol 80

Retinol Social Media Skincare Routine Skincare 80

Eminence Organics

OCTOBER 31, 2023

The Dos And Don'ts Of Facial Steaming Written By (old): Libby Wright Are you looking for a luxurious facial treatment that you can do between your visits to the spa? Lavender oil is known to lessen redness and irritation caused by dry skin and eczema. What Is Facial Steaming?

Facials 97

Facials Sebum Moisturization Hydration 97

Eminence Organics

OCTOBER 31, 2023

The Dos And Don'ts Of Facial Steaming Written By: Libby Wright Are you looking for a luxurious facial treatment that you can do between your visits to the spa? Lavender oil is known to lessen redness and irritation caused by dry skin and eczema. What Is Facial Steaming?

Facials 96

Facials Sebum Moisturization Hydration 96

The Dermatology Digest

FEBRUARY 14, 2024

VTAMA cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S. VTAMA cream, 1% data indicated no new safety or tolerability signals of concern in this population including children 2 years of age and older.

Dermatitis 74

Dermatitis Office Management Eczema 74

The Dermatology Digest

SEPTEMBER 26, 2024

The safety profile was consistent with that previously reported, the study showed. Safety is not an issue. At Week 56, IGA 0/1 was achieved in 47% and 49% and EASI-75 in 73% and 79% of patients with previous nemolizumab and nemolizumab-naïve patients, respectively. Improvements in itch, sleep, and QoL were also observed over time.

Dermatitis 74

Dermatitis Safety Management Eczema 74

The Dermatology Digest

DECEMBER 15, 2023

The comprehensive safety analysis establishes evidence regarding the safety of systematic Janus kinase inhibitors in patients with atopic dermatitis. They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022.

Safety 36

Safety Dermatitis Dermatology Management 36

The Dermatology Digest

DECEMBER 15, 2023

They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022. The post Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD appeared first on The Dermatology Digest.

Safety 36

Safety Dermatitis Dermatology Management 36

The Dermatology Digest

DECEMBER 15, 2023

“The approval of Adbry for pediatric patients living with moderate-to-severe atopic dermatitis expands the therapeutic options for those living with this disease who historically have had a limited selection to choose from,” says Julie Block, President and CEO of the National Eczema Association, in a news release.

Eczema 36

Eczema Dermatitis Safety Therapy 36

The Dermatology Digest

DECEMBER 15, 2023

“The approval of Adbry for pediatric patients living with moderate-to-severe atopic dermatitis expands the therapeutic options for those living with this disease who historically have had a limited selection to choose from,” says Julie Block, President and CEO of the National Eczema Association, in a news release.

Eczema 36

Eczema Dermatitis Safety Therapy 36

US Dermatologt Partners

SEPTEMBER 23, 2024

It’s important to develop healthy skin habits to slow the signs of aging around the eyes, and there are also dermatologic treatment options available when you need to hit the reset button.” Chronic skin conditions – poorly managed chronic skin conditions like eczema and dermatitis may damage or dilate blood vessels around the eyes.

Treatments 41

Treatments Chemical Peels Skincare Routine Sun Protection 41

The Dermatology Digest

OCTOBER 26, 2024

Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study. achieved an Eczema Area and Severity Index (EASI) of 75, 90, and 100, respectively. In the switchers, 47.6%

Dermatitis 36

Dermatitis Treatments Pharmaceutical Eczema 36

The Dermatology Digest

JANUARY 30, 2024

Five investigators have received funding through the 2023 PeDRA Research Grants, Career Bridge Research Grant, Pediatric Alopecia Areata Challenge Grant, and Childhood Eczema Challenge Grant programs. The post And the Winners Are…PeDRA Announces 2023 Grant Recipients appeared first on The Dermatology Digest.

Partnerships 36

Partnerships Eczema Hospital Dermatology 36

The Dermatology Digest

JANUARY 11, 2024

of atopic dermatitis (AD) patients using Vtama (tapinarof) cream, 1% achieved Eczema Area and Severity Index (EASI )75 in an integrated analysis of all the ADORING Program studies, Dermavant reports. Vtama cream, 1% is currently approved for the topical treatment of plaque psoriasis in adults in the U.S. Fully 80.7%

Dermatitis 36

Dermatitis Safety Eczema Sensitive Skin 36

First Derm

DECEMBER 26, 2023

Consult Healthcare Providers When Necessary : Seek professional advice for persistent, severe, or unusual scalp symptoms to ensure accurate diagnosis and effective treatment. 3] Treatment – Dandruff Shampoos: Key Ingredients : Ketoconazole, selenium sulfide, pyrithione zinc, coal tar, salicylic acid.

Management 49

Management Dermatitis Eczema Consultation 49

The Dermatology Digest

MAY 6, 2024

The Phase 2a trial ( NCT05984784 ) evaluates the safety, pharmacokinetics, and efficacy of IMG-007 in adult patients with moderate-to-severe AD who had inadequate response to and/or intolerant of topical therapies. Key study endpoints include safety and percent change from baseline in eczema area and severity index (EASI) over time.

Safety 36

Safety Therapy Dermatitis Dermatology 36

The Dermatology Digest

MARCH 7, 2024

The drug demonstrated significant and clinically relevant improvements in itch, patient-assessed quality-of-life indicators, inflammation, and safety, with minimal side effects and strong patient tolerability when compared to baseline.

Safety 36

Safety Dermatitis Eczema Clinic 36

The Dermatology Digest

DECEMBER 15, 2023

“The approval of Adbry for pediatric patients living with moderate-to-severe atopic dermatitis expands the therapeutic options for those living with this disease who historically have had a limited selection to choose from,” says Julie Block, President and CEO of the National Eczema Association, in a news release.

Eczema 28

Eczema Dermatitis Safety Therapy 28

The Dermatology Digest

APRIL 22, 2024

Adult atopic dermatitis (AD) patients previously treated with dupilumab (Dupixent, Regeneron and Sanofi) who received 400mg eblasakimab weekly achieved Eczema Area Severity Index (EASI) 90, and 66.7% Treatment was well-tolerated and no new safety signals were identified.

Pharmaceutical 36

Pharmaceutical Dermatitis Eczema Injections 36

The Dermatology Digest

JANUARY 23, 2024

The two 48-week randomized, placebo-controlled double-blind, phase 3 studies, ARCADIA 1 and ARCADIA 2 ( N =787) comprised a 16-week initial treatment period followed by a 32-week maintenance period. Safety was assessed throughout the study. in ARCADIA 2 when compared with placebo.

Dermatitis 36

Dermatitis Safety Eczema Sustainability 36

Eminence Organics

JANUARY 19, 2024

Desincrustation is a deep cleansing treatment that's effective in preparing oily or congested skin for extractions. This key treatment leaves the skin with improved skin texture and health, making it an ideal choice for oily or congested skin. Enhances Skin Care Absorption: Desincrustation prepares the skin for subsequent treatments.

Pores 52

Pores Sebum Extractions Dark Spots 52

The Dermatology Digest

DECEMBER 19, 2023

Over three months of treatment, patients received 250mg ADX-629, administered orally twice daily. The primary endpoint of the clinical trial was safety and tolerability. Relative to baseline, over three months of treatment, improvement was observed in all patients. Statistical significance was achieved for improvement in EASI.

Dermatitis 36

Dermatitis Eczema Clinic Therapy 36

The Dermatology Digest

JANUARY 14, 2024

The overwhelming majority of people with atopic dermatitis (AD) treated with investigational roflumilast cream 0.15% (Zoryve, Arcutis) showed a measurable improvement in Eczema Area and Severity Index (EASI) in 4 weeks, according to new pooled analyses from two Phase 3 studies. Fully 91.5% Importantly, EASI-90 was observed in 22.4%

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

The Dermatology Digest

MARCH 11, 2024

Food and Drug Administration (FDA) recently accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). No new safety signals were observed in this trial.

Dermatitis 36

Dermatitis Safety Dermatology Eczema 36

The Dermatology Digest

MARCH 11, 2024

Sanofi’s investigational OX40-ligand blocker amlitelimab produces sustained improvement in the signs and symptoms of atopic dermatitis (AD) in adults who previously responded and continued treatment and sustained off-drug improvements in those who stopped treatment. of patients withdrawn from treatment, the study showed.

Sustainability 36

Sustainability Dermatitis Safety Hospital 36

US Dermatologt Partners

MARCH 27, 2024

While dermatologists and research scientists haven’t decided on one name for this cutting-edge treatment, red light therapy is quickly gaining popularity thanks to the skin-rejuvenating results researchers are noting in research studies. Improves psoriasis , rosacea , acne , and eczema side effects. What is Red Light Therapy?

Therapy 41

Therapy Treatments Dermatology Collagen 41